Botox for Sleep Effectiveness
- 14 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 31 (3) , 194-200
Abstract
Importance: Nocturia is one of the most bothersome complaints in women with overactive bladder syndrome (OAB). Although small preliminary studies have shown that intradetrusor onabotulinum toxin A (BTX) injections reduce nocturia episodes, it is not known how reduction in nighttime urination affects sleep quality and quality of life. Objectives: We aimed to assess the effect of BTX on nocturia frequency, sleep quality, and quality of life. Study Design: This is a prospective observation study of adult women with ≥2 nocturia episodes and OAB planning to undergo treatment with BTX injections. Participants completed a 2-day bladder/sleep diary and sleep-related questionnaires at baseline and 5 weeks post-BTX. Results: A total of 40 participants were included with a mean age of 71 ± 12 years and most (90%) undergoing 100 units of BTX injection. At baseline, the median nocturia episodes were 3.5 (IQR, 2.5–5.0), and nearly half (43%) of participants reported mild to moderate sleep disturbance. At 5 weeks post-BTX, we found a significant decrease in nocturia episodes (−2/night) and a 59% decrease in mild to moderate sleep disturbance (P = 0.006). There were significant increases in longest sleep interval (+1.5 hours), time to first awakening (+1.6 hours) and average sleep interval (+1.3 hours), and a significant increase in nocturia-related quality of life scores (P < 0.001 for all). Sixteen (40%) of participants had nocturia resolution defined as ≤1 mean nocturia episode post-BTX. Conclusions: For women with OAB and >2 nocturia episodes/night, BTX injections reduce voids/night and improve sleep quality and nocturia-related quality of life.Keywords
This publication has 31 references indexed in Scilit:
- International Continence Society consensus on the diagnosis and treatment of nocturiaNeurourology and Urodynamics, 2019
- International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract functionNeurourology and Urodynamics, 2019
- OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in WomenJAMA, 2016
- Can botox improve night‐time overactive bladder symptoms in women?Neurourology and Urodynamics, 2016
- An overactive bladder symptom and health-related quality of life short-form: Validation of the OAB-q SFNeurourology and Urodynamics, 2014
- Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injectionArchives of Gynecology and Obstetrics, 2012
- Early Effect on the Overactive Bladder Symptoms following Botulinum Neurotoxin Type A Injections for Detrusor OveractivityEuropean Urology, 2008
- The Impact of Nocturia in Patients with LUTS/BPH: Need for New RecommendationsEuropean Urology Supplements, 2006
- Degree of bother caused by nocturia in womenNeurourology and Urodynamics, 2004
- Prevalence and burden of overactive bladder in the United StatesWorld Journal of Urology, 2003